Search ARM

Diorasis Therapeutics (Boston) is a preclinical stage opthalmic company developing gene therapy for glaucoma. Non-compliance is the main issue of glaucoma treatment. 120K patients go blind in the US despite availability of low-cost intraocular pressure lowering drops, Our disease-modifying gene agnostic single intracameral injection gene therapy produces tissue plasminogen activator (tPA) that normalizes trabecular meshwork outflow and IOP .

Contact Diorasis Therapeutics
Visit Website